Similarly, a recent study has shown that expression of ARV7 in circulating tumor cells (CTCs) correlated with therapy response and survival in metastatic CR-PCa patients receiving the second generation ADT agents enzalutamide or abiraterone (Table 2); in that, patients with ARV7-positive CTCs had lower PSA response rates and shorter median overall survival [137]. Here, KLK3 is linked to posterior cortical atrophy.